Cargando…

DNase I levels and disease outcome in JIA patients treated with etanercept

Detalles Bibliográficos
Autores principales:	Lazarević, D, Vojinović, J, Sušić, G, Damjanov, N, Bašić, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194526/ http://dx.doi.org/10.1186/1546-0096-9-S1-P171

Ejemplares similares

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
por: Vojinovic, J, et al.
Publicado: (2011)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
por: Susic, G, et al.
Publicado: (2013)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

Does childhood health assessment questionnaire can predict outcome of patients with juvenile idiopathic arthritis?
por: Susic, G, et al.
Publicado: (2011)

A closer look into DNase I hypersensitivity
por: He, Housheng Hansen, et al.
Publicado: (2013)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

KIR-HLA class I combinations in JIA-associated uveitis
por: Parsa, Miriam, et al.
Publicado: (2012)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

A case of chronic recurrent multifocal osteomyelýtýs successfully treated with etanercept
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

Pregnancy outcomes in women affected by juvenile idiopathic arthritis (JIA)
por: Alpigiani, Maria Giannina, et al.
Publicado: (2014)

Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?
por: Cron, Randy Q, et al.
Publicado: (2010)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

Imaging of refractory chronic recurrent multifocal osteomyelitis succesfully treated with etanercept and methotrexate
por: Quesada-Masachs, Estefania, et al.
Publicado: (2014)

Influence of rhDNAse on the duration of mechanical ventilation in intensive care patients
por: Deschner, N, et al.
Publicado: (2008)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Use of internet in adolescents and young adults with JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

JIA-like in a boy with Ataxia-telangiectasia
por: Furtado, Filipa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k1tpfhaf6ruqjdi90vfh4gk1jg